Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective: To compare the different polycystic ovarian syndrome (PCOS) phenotypes based on their clinical, metabolic, hormonal profile, and their differential response to clomiphene. Design: Prospective observational study. Setting: Infertility clinic, a government hospital. Sample Size: 164 women with PCOS-related infertility. Materials and Methods: Sample population was divided into four phenotypes based on the NIH (National Institute of Health) consensus panel criteria. The incremental dose of clomiphene from 50 to 150 mg/day over three cycles was given. Outcome Measures: Clinical history, metabolic, hormonal profile, and ultrasound features of each phenotype. Also, the response to clomiphene citrate was studied as presence or absence of ovulation. Results: The prevalence of phenotypes A, B, C, and D were 67.7%, 11%, 17.7%, and 3.6%, respectively. Phenotype A had significantly higher weight, body mass index, clinical, and biochemical hyperandrogenism, menstrual irregularities, ovarian reserve parameters, fasting insulin, HOMA-IR, and more deranged lipid profile ( P < 0.05). Clomiphene resistance was significantly more common in phenotype A ( P < 0.05). No significant differences were noted in the waist circumference, waist-hip ratio, blood pressure and blood sugar values (fasting, 1-hour postprandial, 2-hour postprandial). Also, the Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), LH-FSH ratio, 17-hydroxyprogesterone, and vitamin D levels were not significantly different among various PCOS phenotypes. Conclusion: Full-blown PCOS (phenotype A) is at a higher risk of adverse metabolic and cardiovascular outcomes as compared with the others, and phenotype D is the least severe phenotype. Thus, the phenotypic division of patients with PCOS-related infertility can help in prognosticating the patients about the severity of the disease and the fertility outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Criteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.003 · Cited by 1,358
Yildiz, B. O., Bozdag, G., Yapici, Z., Esinler, I., & Yarali, H. (2012) · Human Reproduction · doi:10.1093/humrep/des232 · Cited by 704
DeUgarte, C. M., Bartolucci, A. A., & Azziz, R. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.070 · Cited by 589
Research works printed but not linked: 14
- Kim, 2014, Prevalence of metabolic syndrome is higher among non-obese PCOS women with hyperandrogenism and menstrual irregularity in Korea, PLoS One, 9, e99252, 10.1371/journal.pone.0099252 · DOI
- Gambineri, 2012, Polycystic ovary syndrome is a risk factor for type 2 diabetes: Results from a long-term prospective study, Diabetes, 61, 2369, 10.2337/db11-1360 · DOI · Paper page
- Zawadzski, 1992, Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach, Polycystic Ovary Syndr, 39
- Georgopoulos, 2014, Elevated serum androstenedione is associated with a more severe phenotype in women with polycystic ovary syndrome (PCOS), Hormones (Athens), 13, 213, 10.1007/BF03401335 · DOI
- Nishida, 2010, Body fat distribution and noncommunicable diseases in populations: Overview of the 2008 WHO expert consultation on waist circumference and waist-hip ratio, Eur J Clin Nutr, 64, 2, 10.1038/ejcn.2009.139 · DOI · Paper page
- Wild, 2005, Ferriman gallwey self-scoring I: Performance assessment in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 4112, 10.1210/jc.2004-2243 · DOI · Paper page
- Whitaker, 2016, Abnormal uterine bleeding, Best Pract Res Clin Obstet Gynaecol, 34, 54, 10.1016/j.bpobgyn.2015.11.012 · DOI · Paper page
- 2002, Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 · DOI · Paper page
- Ray, 2012, A simple way to identify insulin resistance in non-diabetic acute coronary syndrome patients with impaired fasting glucose, Indian J Endocrinol Metab, 16, S460
- Gluszak, 2012, Phenotype and metabolic disorders in polycystic ovary syndrome, ISRN Endocrinol, 569862
- Pehlivanov, 2007, Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population, Gynecol Endocrinol, 23, 604, 10.1080/09513590701536246 · DOI · Paper page
- Zhang, 2009, Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population, BJOG, 116, 1633, 10.1111/j.1471-0528.2009.02347.x · DOI · Paper page
- Franks, 2006, Development of polycystic ovary syndrome: Involvement of genetic and environmental factors, Int J Androl, 29, 278, 10.1111/j.1365-2605.2005.00623.x · DOI · Paper page
- Diamanti-Kandarakis, 1998, Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome, Eur J Endocrinol, 138, 269, 10.1530/eje.0.1380269 · DOI · Paper page
Cited by
Uysal, E., Tammo, O., Soylemez, E., Incebıyık, M., Filiz, D., & Alci, M. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01701-6 · Cited by 23
Phimphasone-Brady, P., Palmer, B., Vela, A., Johnson, R. L., Harnke, B., Hoffecker, L., Coons, H. L., & Epperson, C. N. (2022) · F&S Reviews · doi:10.1016/j.xfnr.2021.11.004 · Cited by 20
Dietary Patterns and Metabolic and Hormonal Parameters in Women with Suspected PCOS
Kowalczyk, K., Kadłubek, S., Krużel, A., Sikora, D., Daniluk, J., & Madej, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082708 · Cited by 4
“…Phenotype B (androgen excess and ovulatory dysfunction, without polycystic ovarian morphology), Phenotype C (androgen excess and polycystic ovarian morphology, without ovulatory dysfunction), and Phenotype D (ovulatory dysfunction and polycystic ovarian morphology, without androgen excess) [8].”
Metadata
- Authors
- Gainder, S., Sachdeva, G., Suri, V., Sachdeva, N., & Chopra, S.
- Venue
- Indian Journal of Endocrinology and Metabolism
- Publisher
- Medknow
- Published
- 2019
- Volume
- 23
- Issue
- 3
- Pages
- 326
- ISSN
- 2230-8210 (ISSN-L)
- OpenAlex
- W2965877220
- Cited by
- 126
- References
- 6
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.